TY - JOUR
T1 - A risk identification model for detection of patients at risk of antidepressant discontinuation
AU - Zolnour, Ali
AU - Eldredge, Christina E.
AU - Faiola, Anthony
AU - Yaghoobzadeh, Yadollah
AU - Khani, Masoud
AU - Foy, Doreen
AU - Topaz, Maxim
AU - Kharrazi, Hadi
AU - Fung, Kin Wah
AU - Fontelo, Paul
AU - Davoudi, Anahita
AU - Tabaie, Azade
AU - Breitinger, Scott A.
AU - Oesterle, Tyler S.
AU - Rouhizadeh, Masoud
AU - Zonnor, Zahra
AU - Moen, Hans
AU - Patrick, Timothy B.
AU - Zolnoori, Maryam
N1 - Funding Information:
This research was partially supported by the Intramural Research Program of the National Institutes of Health (NIH), National Library of Medicine (NLM) and Lister Hill National Center for Biomedical Communications (LHNCBC).
Publisher Copyright:
Copyright © 2023 Zolnour, Eldredge, Faiola, Yaghoobzadeh, Khani, Foy, Topaz, Kharrazi, Fung, Fontelo, Davoudi, Tabaie, Breitinger, Oesterle, Rouhizadeh, Zonnor, Moen, Patrick and Zolnoori.
PY - 2023
Y1 - 2023
N2 - Purpose: Between 30 and 68% of patients prematurely discontinue their antidepressant treatment, posing significant risks to patient safety and healthcare outcomes. Online healthcare forums have the potential to offer a rich and unique source of data, revealing dimensions of antidepressant discontinuation that may not be captured by conventional data sources. Methods: We analyzed 891 patient narratives from the online healthcare forum, “askapatient.com,” utilizing content analysis to create PsyRisk—a corpus highlighting the risk factors associated with antidepressant discontinuation. Leveraging PsyRisk, alongside PsyTAR [a publicly available corpus of adverse drug reactions (ADRs) related to antidepressants], we developed a machine learning-driven algorithm for proactive identification of patients at risk of abrupt antidepressant discontinuation. Results: From the analyzed 891 patients, 232 reported antidepressant discontinuation. Among these patients, 92% experienced ADRs, and 72% found these reactions distressful, negatively affecting their daily activities. Approximately 26% of patients perceived the antidepressants as ineffective. Most reported ADRs were physiological (61%, 411/673), followed by cognitive (30%, 197/673), and psychological (28%, 188/673) ADRs. In our study, we employed a nested cross-validation strategy with an outer 5-fold cross-validation for model selection, and an inner 5-fold cross-validation for hyperparameter tuning. The performance of our risk identification algorithm, as assessed through this robust validation technique, yielded an AUC-ROC of 90.77 and an F1-score of 83.33. The most significant contributors to abrupt discontinuation were high perceived distress from ADRs and perceived ineffectiveness of the antidepressants. Conclusion: The risk factors identified and the risk identification algorithm developed in this study have substantial potential for clinical application. They could assist healthcare professionals in identifying and managing patients with depression who are at risk of prematurely discontinuing their antidepressant treatment.
AB - Purpose: Between 30 and 68% of patients prematurely discontinue their antidepressant treatment, posing significant risks to patient safety and healthcare outcomes. Online healthcare forums have the potential to offer a rich and unique source of data, revealing dimensions of antidepressant discontinuation that may not be captured by conventional data sources. Methods: We analyzed 891 patient narratives from the online healthcare forum, “askapatient.com,” utilizing content analysis to create PsyRisk—a corpus highlighting the risk factors associated with antidepressant discontinuation. Leveraging PsyRisk, alongside PsyTAR [a publicly available corpus of adverse drug reactions (ADRs) related to antidepressants], we developed a machine learning-driven algorithm for proactive identification of patients at risk of abrupt antidepressant discontinuation. Results: From the analyzed 891 patients, 232 reported antidepressant discontinuation. Among these patients, 92% experienced ADRs, and 72% found these reactions distressful, negatively affecting their daily activities. Approximately 26% of patients perceived the antidepressants as ineffective. Most reported ADRs were physiological (61%, 411/673), followed by cognitive (30%, 197/673), and psychological (28%, 188/673) ADRs. In our study, we employed a nested cross-validation strategy with an outer 5-fold cross-validation for model selection, and an inner 5-fold cross-validation for hyperparameter tuning. The performance of our risk identification algorithm, as assessed through this robust validation technique, yielded an AUC-ROC of 90.77 and an F1-score of 83.33. The most significant contributors to abrupt discontinuation were high perceived distress from ADRs and perceived ineffectiveness of the antidepressants. Conclusion: The risk factors identified and the risk identification algorithm developed in this study have substantial potential for clinical application. They could assist healthcare professionals in identifying and managing patients with depression who are at risk of prematurely discontinuing their antidepressant treatment.
KW - adverse drug events
KW - antidepressant discontinuation
KW - antidepressant effectiveness
KW - content analysis
KW - machine learning
KW - online healthcare forums
UR - http://www.scopus.com/inward/record.url?scp=85170367507&partnerID=8YFLogxK
U2 - 10.3389/frai.2023.1229609
DO - 10.3389/frai.2023.1229609
M3 - Article
AN - SCOPUS:85170367507
SN - 2624-8212
VL - 6
SP - 1
EP - 14
JO - Frontiers in Artificial Intelligence
JF - Frontiers in Artificial Intelligence
M1 - 1229609
ER -